Alnylam Pharmaceuticals
ALNY
#549
Rank
A$64.13 B
Marketcap
A$485.45
Share price
-2.52%
Change (1 day)
9.94%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$0.15

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$0.13. In 2023 the company made an earnings per share (EPS) of A-$5.07 an increase over its 2022 EPS that were of A-$13.34.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.15
2023A-$5.07-62%
2022A-$13.3429.03%
2021A-$10.34-3.36%
2020A-$10.70-8.48%
2019A-$11.697.67%
2018A-$10.8639.74%
2017A-$7.7712.94%
2016A-$6.8838.84%
2015A-$4.95-32.88%
2014A-$7.38259.44%
2013A-$2.05-31.25%
2012A-$2.99

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$10.57 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$5.32 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$62.38 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.93-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.05-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.34-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$0.90 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$1.79-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA